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INTRODUCTION
NF-κB
Nuclear factor-κB (NF-κB) was identified twenty years ago as a regulator of 
expression  of  the  κB  light  chain  in  B  cells. NF-κB  transcription  factors  are 
important in integrating multiple stress stimuli and regulating innate and adaptive 
immune responses seen in states of inflammation (1).
The NF-κB family of transcription factors consists of five members, p50, p52, 
p65 (RelA),  c-Rel  and RelB,  which share an N-terminal  Rel  homology domain 
(RHD) responsible for DNA binding and homo- and heterodimerization (Figure 1). 
NF-κB dimers bind to κB sites within the promoters/enhancers of target genes and 
regulate transcription through the recruitment of coactivators and corepressors. The 
transcription  activation  domain  (TAD),  necessary  for  the  positive  regulation  of 
gene expression, is present only in p65, c-Rel and RelB. As they lack TADs, p50 
and p52 may repress transcription unless associated with a TAD-containing NF-κB 
family member or other proteins capable of coactivator recruitment.
Crystal  structures  of  NF-κB  dimers  bound  to  κB  sites  reveal  how  the 
immunoglobulin-like domains that comprise  the RHD contact  DNA. The NH2  –
terminal Ig-like domain confers selectivity for certain types of κB sites, whereas the 
hydrophobic  residues  within  the  C-terminal  domain  provide  the  dimerization 
interface between NF-κB subunits. Although RHD and TAD function are typically 
considered independent, both domains undergo posttranslational modifications that 
can affect NF-κB transcriptional activity as well as DNA binding (Figure 1).
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Figure 1. The NF-κB, IκB, and IKK Protein Families
In its inactive state,  NF-κB dimers are associated with one of three typical IκB 
proteins, IκBα, IκBβ, or IκB , or the precursor proteins p100 and p105. These IκBs 
maintain NF-κB dimers in the cytoplasm and are crucial for signal responsiveness. 
There  are  two inducibly  expressed,  atypical  IκB proteins,  Bcl-3  and IκBζ,  that 
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function  quite  differently  in  the  regulation  of  NF-κB.  Lastly  an  alternative 
transcript  of  the  p105  gene  in  mouse  encodes  an  IκB  molecule,  IκBγ,  whose 
biological role remains unclear. All IκB proteins are characterized by the presence 
of  multiple  ankyrin  repeat  domain  (Figure  1).  The  prototypical  and  most 
extensively studied member of the family is IκBα. IκBα is rapidly degraded during 
activation of canonical NF-κB signaling pathways leading to the release of multiple 
NF-κB dimers,  although the p65:p50 heterodimer is likely the primary target of 
IκBα. The established model of IκB function posits that IκBα retains NF-κB dimers 
in  the cytoplasm,  thereby preventing their  nuclear  translocation  and subsequent 
DNA  binding;  however,  the  situation  is  actually  more  complex.  The  crystal 
structure of IκBα bound to the p65/p50 heterodimer reveals that the IκBα protein 
masks only the nuclear localization sequence (NLS) of p65, whereas the NLS of 
p50  remains  exposed.  The  exposed  NLS  of  p50  coupled  with  nuclear  export 
sequences  (NES)  in  IκBα and  p65  leads  to  constant  shuttling  of  IκBα/NF-κB 
complexes between the nucleus and the cytoplasm, despite steady-state localization 
that appears almost exclusively cytosolic (2). Degradation of IκBα drastically alters 
the dynamic balance between cytosolic and nuclear localization signals to favor 
nuclear localization of NF-κB. The noncanonical or alternative NF-κB pathway, 
however,  proceeds  through  proteasomal  processing,  rather  than  degradation,  of 
p100  to  p52,  thereby  liberating  p52  containing  NF-κB  dimers  that  drive  a 
transcriptional response that is distinct from that induced by the canonical, IκBα-
regulated pathway. In part because IκBα degradation and p100 processing regulate 
different  populations  of  NF-κB  dimers,  canonical  and  noncanonical  NF-κB 
pathways regulate distinct sets of target genes (Figure 2). 
Degradation of IκB is a rapidly induced signaling event that is initiated upon 
specific phosphorylation of these molecules by activated IKK. The IKK complex 
contains two highly homologous kinase subunits, IKKα and IKKβ, and a regulatory 
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subunit NEMO (NF-κB essential modulator) (3). Although they are generally found 
in  a  heteromeric  kinase  complex,  IKKα and  IKKβ are  somewhat  selectively 
required  for  specific  NF-κB  signaling  pathways.  In  most  canonical  NF-κB 
signaling, e.g., downstream of TNFR1, IKKβ is both necessary and sufficient for 
phosphorylation of IκBα on Ser32 and Ser36 and of IκBβ on Ser19 and Ser23. 
While  not  generally  required  for  IκBα phosphorylation  and  degradation  in 
canonical  signaling  pathways,  IKKα can  mediate  IκBα phosphorylation  and 
appears  to  play  a  critical  role  in  canonical  NF-κB-dependent  transcriptional 
responses.  The  noncanonical  pathway,  conversely,  depends  only  on  the  IKKα 
subunit,  which  functions  by  phosphorylating  p100  and  causing  its  inducible 
processing to p52. The noncanonical pathway is activated by a subset of TNFR 
superfamily members, while the canonical pathway is activated by a broader and 
overlapping array of receptors (Figure 2).
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Figure 2. NF-κB signaling pathways
Phosphorylation of the conserved serine residues (DS*GXXS*) in IκB proteins 
results  in their  K48-linked polyubiquitination by  βTrCP containing Skp1-Culin-
Roc1/Rbx1/Hrt-1-F-box  (SCF)  E3  ubiquitin  ligase  complexes  (SCFβTrCP) 
coordinately with the E2 UbcH5 (4). The released NF-κB dimers bind promoter 
and enhancer regions containing  κB consensus sequences 5′ GGGRNWYYCC 3′ 
(N—any base; R—purine; W—adenine or thymine; and Y—pyrimidine) (5). The 
degenerate  nature  of  the  κB  site  sequence,  which  shows  far  greater  sequence 
variability  than  the  consensus  sequence  given  here,  combined  with  the  varied 
binding preferences of NF-κB dimers yields the large list of NF-κB-regulated genes 
(6).  Transcription  of  target  genes  is  further  regulated  through  posttranslational 
modifications of NF-κB that affect  the ability of NF-κB dimers to interact with 
transcriptional coactivators. NF-κB-dependent transcription of IκB proteins as well 
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as  additional  mechanisms  targeting  DNA-bound  NF-κB  dimers  terminate  the 
response (7).
NF-κB and cancer
Activation of NF-κB (usually assessed by the presence of nuclear RelA) has 
been observed in  many  cancers,  including but  not  limited  to  breast  cancer  (8), 
melanoma  (9),  lung  cancer  (10),  colon  cancer  (11),  multiple  myeloma  (12), 
pancreatic  cancer  (13),  esophageal  adenocarcinoma  (14),  and  various  types  of 
leukemias (15-17) and lymphomas (18-19). The presence of activated NF-κB in 
tumors does not, however, establish a causal link. Only with the advent of recent 
advances in experimental mouse models of cancer have investigators been able to 
tie specific functions of NF-κB activation to the carcinogenesis process, as well as 
tumor progression and metastatogenesis (20). 
The  role  of  NF-κB in  solid  tumors  has  been  well  documented  in  several 
studies  performed  on  primary  tumors  and  neoplastic  cell  lines  derived  from 
different human tissues. These studies show that the inhibition of constitutive NF-
κB activity blocks the oncogenic potential of neoplastic cells by different ways: by 
sensitizing tumor cells to chemotherapeutic drug-induced apoptosis, by decreasing 
the highly proliferative rate which characterizes transformed cells,  by inhibiting 
tissue  invasiveness  and  metastatic  potential  of  highly  malignant  cells  (21).  In 
addition, since it is now generally accepted that chronic inflammation contributes 
to the genesis of many solid tumors, such as gastric, colon or hepatic carcinomas, it 
has been recently shown that activation of NF-κB by the classical IKKβ-dependent 
pathway,  is  a  crucial  mediator  of  inflammation-induced  tumor  growth  and 
progression  in  animal  models  of  inflammation-associated  cancer  (22-23). 
Therefore,  NF-κB is able to regulate the expression and the function of a wide 
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spectrum of genes involved in the control  of cell  cycle,  apoptosis,  cell  growth, 
tissue invasiveness and inflammation. It is just this ability that makes NF-κB the 
crucial point of convergence of a number of stimuli  that can influence different 
aspects of cellular homeostasis and, therefore, can lead to the onset of cancer. 
According to  Hanahan  and Weinberg  (24),  six  essential  alterations  in  cell 
physiology characterize  a  tumor cell:  self-sufficiency in growth,  insensitivity  to 
growth-inhibitory  signals,  evasion  of  apoptosis,  limitless  replicative  potential, 
sustained angiogenesis and tissue invasion and metastasis. Many of the genes able 
to mediate such effects are under  transcriptional control of NF-κB (25) (Figure 3). 
In fact, the activity and the expression of Cyclin D1 (26), CDK2 kinase (27), c-myc 
(28), which are involved in the control of cell cycle and are altered in several types 
of cancer, such as breast, prostate and ovarian tumors, are regulated by NF-κB. The 
expression  and the function  of  numerous  cytokines,  that  are  growth factors  for 
tumor cells,  are NF-κB-dependent.  Among them are: IL-1β, a growth factor for 
acute myeloid leukemia (AML), TNF, a growth factor for Hodgkin's lymphoma, 
cutaneous T cell  lymphoma and gliomas,  interleukin (IL)-6, a growth factor for 
multiple  myeloma  (29).  Some growth factors,  such  as  epidermal  growth factor 
(EGF), or receptors for growth factors, such as HER2, able to promote growth of 
solid  tumors,  activate  NF-κB (30).  Tissue  invasion  and  metastasis,  two  crucial 
events of tumor progression, are regulated by NF-κB-dependent genes, including 
matrix metalloproteinases (MMPs) (31), urokinase type of plasminogen activator 
(uPA) (32), IL-8 (33), the adhesion molecules VCAM-1, ICAM-1 and ELAM-1 
(34) and chemokine receptors such as CXCR4 (35). NF-κB activity is also involved 
in the regulation of angiogenesis, the process by which tumor cells promote neo-
vascularization,  an  essential  step  for  their  growth  and  invasiveness.  Vascular 
endothelial growth factor (VEGF), which is the main member of angiogenic factors 
family, is under transcriptional control of NF-Κb (36). Finally, altered expression 
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of genes involved in regulation of apoptosis, which is a feature of neoplastic cells, 
is  often  due  to  deregulated  NF-κB  activity.  TNF  receptor  associated  factor 
(TRAF)1/2 (37), IAP proteins (XIAP, cIAP-1 and -2) (37-38), members of Bcl-2 
family (39), c-FLIP (40), GADD45β (41), Ferritin Heavy Chain (42) are all anti-
apoptotic genes. By promoting cell survival, these genes lead to the maintaining of 
cell-transformed state and are responsible for the resistance to chemotherapeutic 
drugs.  Therefore,  it  is  not  surprising  that  altered  NF-κB  promotes  neoplastic 
transformation by controlling expression of these genes. In fact, inactivation of NF-
κB in different cell lines derived from tumors displaying high constitutive NF-κB 
activity, leads to the loss of their tumorigenic potential due to either an increased 
susceptibility  to  apoptosis  or  a  decrease  of  their  uncontrolled  proliferative  rate. 
Moreover, in some cases, blocking NF-κB activity inhibits the metastatic potential 
of many cancer cell lines or reduces the tumor size (Figure 3). 
13
Fig. 3 NF-κB contributes to cancer development through regulation of different genes involved in 
oncogenesis. According to Hanahan and Weinberg, six essential alterations in cell physiology 
characterize a tumor cell: self-sufficiency in growth, insensitivity to growth-inhibitory signals, 
evasion of apoptosis, limitless replicative potential, sustained angiogenesis and tissue invasion 
and metastasis. Many of the genes able to mediate such effects are under transcriptional control 
of NF-κB.
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What  is  the  cause  of  NF-κB  constitutive  activation  in  tumors?  The 
mechanisms determining persistent and de-regulated NF-κB activity in cancer cells 
are not well understood. Since NF-κB signaling pathway is tightly controlled by 
several regulatory proteins, the constitutive activation of NF-κB in solid tumors has 
been mainly attributed to disruption of this process (i.e., defective IκBα activity, 
constitutive IKK activity, enhanced proteasomal activity), consistent with scenario 
observed in NF-κB-associated haematological malignancies. Another possibility is 
that constitutive NF-κB activation could be determined by prolonged and persistent 
stimulation of cancer cells by factors promoting induction of NF-κB signaling by 
autocrine or paracrine fashion. Thus, NF-κB activity is held at high levels until this 
autocrine or paracrine loop is not interrupted.
 NF-κB links inflammation and cancer
For many years, a link between inflammation and cancer has been strongly 
suspected. The Greek doctor Galen two millenniums ago, noticed a link between 
inflammation and cancer. In the 19th century Wirkow suggested that tumors may 
arise  in  area  of  chronic  inflammation.  More  recently,  population  based  studies 
show that susceptibility to cancer increases when tissues are chronically inflamed, 
and long-term use  of  non-steroidal  anti-inflammatory  drugs  reduces  the  risk  of 
several cancer. 
Inflammation is central to control our fight against pathogens, and to regulate 
wound healing. These are very intricate biological responses that involved complex 
interactions between different cell types that regulate the expression of biological 
mediators which promote cell chemotaxis, cell migration and cell proliferation. If 
inflammation  is  not  ordered and timely,  the resulting chronic inflammation  can 
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contribute to a variety of diseases including cancer. Cells of the innate immune 
system neighbouring the tumor (inflamed area) secrete pro-inflammatory cytokines, 
such  as  TNFα,  IL-1,  IL-6  and  IL-8,  as  well  as  extracellular  matrix-degrading 
enzymes,  growth  factors  and  ROS.  This  microenvironment  enhances  cell 
proliferation,  cell  survival,  cell  migration  and  angiogenesis,  thereby  promoting 
tumor development. Chronic inflammation due to viruses or bacteria infections can 
directly induce mutations in tumor suppressors or oncogenes of epithelial cells, but 
can  also  stimulate  the  formation  of  carcinomas  through an  indirect  mechanism 
involving  activation  of  surrounding  inflammatory  cells.  In  addition,  activated 
innate immune cells can interfere with T cell response to cancer. Macrophages can 
inhibit antigen presentation by dendritic cells, directly suppress T cell response, and 
indirectly down regulate immunity by inducing regulatory T cell through affects of 
IL-10 and TGFβ. Thus,  the ongoing inflammatory response has the capacity  to 
profoundly alter the ability of the host to mount adaptive immune response within 
the  inflammatory  stroma  of  tumors.  The  interplay  between  epithelial  and 
inflammatory cells is thought to be crucial for the genesis and the establishment of 
carcinomas. One of the main actors in inflammatory process is NF-κB which, by 
regulating the expression and the function of different cytokines and chemokines in 
inflammatory cells, stimulates the growth and its own activity in epithelial cells. 
Thus, NF-κB establishes a network that, after prolonged time, can lead epithelial 
cells  to  undergo  malignant  transformation.  For  example,  one  of  the  main  risk 
factors  linked to  gastric  cancer  is  Helicobacter  pylori (H. pylori)  infection.  H. 
pylori is a potent NF-κB activator (43): once NF-κB is activated in gastric cells, it 
induces transcription of IL-1, IL-6, IL-8, TNFα and other growth factors that can 
promote uncontrolled proliferation either by autocrine stimulation or by paracrine 
stimulation of surrounding inflammatory cells. On the other hand, H. pylori induces 
NF-κB-dependent production of COX2, ROS, iNOS that determine DNA damage, 
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thereby increasing the susceptibility to malignant  transformation of gastric cells. 
Another example for the role played by NF-κB in controlling inflammation and 
cancer is represented by colitis-associated cancer.  Ulcerative colitis  is a chronic 
inflammatory bowel disease that, together to Crohn's disease, shows persistent NF-
κB activation in tissue macrophages and epithelial cells of the colonic mucosa. By 
a mechanism similar to that of gastric cells, NF-κB is able to promote colorectal 
cancer. These two examples demonstrate that NF-κB activates a network between 
epithelial  cells  and  inflammatory  cells  that  not  only  leads  to  neoplastic 
transformation,  but also sustains the malignant  phenotype of epithelial  cells.  To 
analyze  in  more  detail  the  molecular  mechanisms  regulating  these  phenomena, 
Karin (22) and Ben-Neriah (23) have independently developed two animal models 
of inflammation-associated cancer, a colitis-associated cancer (CAC) model and a 
genetic model (MDR2−/− mice) of cholangitis (bile-duct inflammation), which leads 
to hepatocarcinoma.
Karin and colleagues showed that the administration of dextran sulfate to mice 
caused chronic colitis which greatly enhanced the incidence of colon carcinomas 
following administration of the pro-carcinogen azoxymethane. Chronic colitis was 
determined by disruption of intestinal barrier and exposure of macrophages in the 
lamina  propria  to  enteric  bacteria.  The  exposure  of  macrophages  to  bacteria 
induced  the  activation  of  NF-κB  in  these  cells,  leading  to  the  production  and 
secretion  of  pro-inflammatory  cytokines  that  activated  NF-κB  in  intestinal 
epithelial cells. It is also possible that necrotic tumor cells may activate adjacent 
macrophages  and/or  other  myeloid  cells  which  than  secrete  growth factors  and 
mediators  of  inflammation.  The  sustained  activation  of  NF-κB  in  enterocytes 
increased the tumor susceptibility  following azoxymethane  stimulation.  If  IKKβ 
was deleted in enterocytes, tumor incidence but not tumor size strongly decreased, 
indicating  that  the  IKKβ-dependent  NF-κB-activation  pathway  operated  during 
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early phases of tumorigenesis. However, deleting IKKβ in myeloid cells, which are 
important for the development of CAC, decreased not only tumor incidence but 
also  tumor  size,  as  a  consequence  of  diminished  proliferation  of  transformed 
enterocytes which requires growth factors produced by myeloid cells (22). Thus, in 
this  model,  NF-κB promotes  survival  of  malignant  cells  either  in  early  or  late 
phases of tumorigenesis, depending on cell types (epithelial or inflammatory cells) 
in which it has been activated. 
Similarly,  Ben-Neriah  and  Co.  demonstrated  that  the  appearance  of 
hepatocarcinoma in  MDR2−/− mice,  a  genetic  model  of  cholangitis,  was  due  to 
prolonged TNF-dependent NF-κB activation of hepatocyte by inflammatory cells 
surrounding  them  in  the  liver.  This  caused  increased  survival  of  dysplastic 
hepatocyte by up-regulation of anti-apoptotic genes such as GADD45β and BFL1. 
The  inactivation  of  NF-κB  by  hepatocyte-specific  expression  of  IκBα super-
repressor, or by suppressing TNF activity blocked tumor development. This effect 
was seen only when NF-κB activity was inhibited between 7 and 14 months after 
mice birth, during late phases of tumor promotion, while its inactivation during the 
first 7 months caused no beneficial effects (23). Therefore, in this mouse model, the 
role of NF-κB was prominent in maintaining rather than in promoting malignant 
transformation of hepatocyte.
The  data  obtained  in  these  two  cancer  models,  suggest  that  the  NF-κB 
pathway does not affect initiation but has multiple actions in tumor promotion, by 
preventing  apoptosis  of  cells  with  malignant  potential,  by  stimulating  the 
production of pro-inflammatory cytokines in the inflammatory cells infiltrating the 
tumor  mass  (Figure  4).  This  model  is  consistent  with  the  observed  correlation 
between  the  number  of  inflammatory  cells,  level  of  cytokines  and  tumor 
aggressiveness and prognosis in both human and mouse. However, the transformed 
cells themselves can contribute to the overall level of secreted pro-inflammatory 
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cytokines, and to maintain the NF-κB pathway activated. In fact, it is possible to 
keep malignant cells in culture without the support of the innate immunity and still 
detect constitutive activation of NF-κB. In addition, at least for some cell types, 
such  as  undifferentiated  thyroid  carcinomas,  it  is  possible  to  detect  an  NF-κB 
modulating activity secreted by the transformed cells (44).
 Fig. 4 Mechanisms by which NF-κB contributes to cancer development during inflammation. 
The interplay between epithelial and inflammatory cells is thought to be crucial for the genesis 
and the establishment of carcinomas. One of the main actors in inflammatory process is NF-κB 
which, by regulating the expression and the function of different cytokines and chemokines in 
inflammatory cells, stimulates the growth and its own activity in epithelial cells. Thus, NF-κB 
establishes a network that can sustain cell proliferation and resistance to apoptosis.
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NGAL protein
The  Neutrophil  Gelatinase-Associated  Lipocalin  (NGAL),  also  known  as 
lipocalin-2,  is  a  member  of  the  large  family  of  lipocalins,  a  group  of  small 
extracellular  proteins  with  great  functional  diversity  (45).  It  is  released  from 
neutrophil granules as a 25 kDa monomer, a 46 kDa disulfide-linked homodimer 
and a 135 kDa disulfide-linked heterodimer with the matrix metalloproteinase-9 
(MMP-9) (46). 
NGAL is thought to be an acute phase protein (47), it is only expressed at the 
myelocyte/metamyelocyte  stage  in  the  course  of  neutrophil  maturation.  Once 
synthesized,  the protein is  stored in the azurophilic granules until  it  is  released 
when the neutrophil  is  activated. As expected,  based  on its  identification as  an 
acute  phase  protein,  elevated  serum NGAL has  been  observed  associated  with 
several  diseases  with  an  inflammatory  component,  including  atherosclerosis, 
ischemic cerebrovascular diseases and inflammatory bowel disease (48). Elevated 
NGAL expression has been also shown in different human tumors, including breast 
(49), lung (50), colon (48), ovary (51) and pancreas (52) carcinomas. However, the 
precise role of NGAL has not been well defined yet. 
Several studies have suggested that NGAL is a potent bacteriostatic agent by a 
siderophore-mediated  sequestering  of  iron (53).  Lipocalin-2-deficient  mice  have 
normal litters and no apparent phenotype when housed in specific pathogen-free 
conditions. However, intraperitoneal challenge with a sub-lethal dose of a clinical 
strain of  Escherichia coli,  H9049, results in substantial  increases in bacteraemia 
and bacterial burden in the liver and spleen. 
The  expression  of  lipocalin  2  in  multiple  tissues  outside  the  setting  of 
infection suggests that it may have other functions, such as have been postulated in 
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kidney  development  and  the  implantation  and  parturition  stages  of  pregnancy. 
Although we cannot exclude a role for lipocalin 2 in these functions, the phenotype 
of lipocalin-2-deficient mice argues against an obligatory role in these biological 
processes (54). 
Another  function  of  NGAL is  represented  by  its ability  of  binding Matrix 
metalloproteinase 9 (MMP-9). This protein has been shown able to promote tumor 
growth  in  a  number  of  studies of  tumor-induced  and  also  to contribute  to  the 
metastatic  and  angiogenic  phenotypes  of  human tumors.  In  engineered  MCF-7 
human breast cancer cell lines, to express elevated levels of NGAL, it is shown that 
NGAL overexpression leads to increased breast tumor growth that is accompanied 
by an increase in MMP-9 activity, tumor angiogenesis, and tumor cell proliferation. 
In addition, the enzymatic activity of urinary MMP-9/NGAL complex was detected 
in  the urine of  breast cancer  patients  but  not  in  the age-matched,  sex-matched, 
healthy control samples. Taken together,  these findings suggest  that NGAL may 
contribute to cancer disease progression, at least in part, by protecting MMP-9 from 
degradation,  thereby enhancing  its  enzymatic  activity  and  facilitating  tumor 
progression. The appearance of MMP-9/NGAL complexes in the urine of breast 
cancer  patients  suggests  that  urinary  MMP-9/NGAL detection  may serve  as  an 
independent predictor of disease status, a noninvasive marker of  cancer diagnostics 
and prognostics (55). 
As a secreted binding protein, it has been reported that the murine ortholog, 
called  24p3,  plays  a  crucial  role  in  IL-3  deprivation-induced  apoptosis  by 
regulating  intracellular  iron  delivery,  very  likely  after  interaction  with  a  24p3 
receptor  (56).  Indeed,  the  human  NGAL  protects  A459  and  MCF7  cells  from 
apoptosis  induced  by  PDK1  inhibitors  (57).  Lastly,  NGAL  induces  cell 
proliferation by promoting the iron dependent metabolism of nucleotides for DNA 
synthesis (58). 
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AIM OF THE WORK
NF-κB  controls  expression  of  a  number  of  pro-inflammatory  factors 
(cytokines, chemokines and growth factors), secreted by cancer cells in the tumor 
microenvironment, which substantially contribute to the tumor development (59-
60). Understanding the molecular mechanism by which these factors play their role 
in cancer, could help in the comprehension of the role of NF-κB in inflammation-
related cancer, and could open new perspectives in the treatment of tumors. 
In the laboratory of Prof Formisano it was previously shown that NF-κB is 
strongly activated in primary human anaplastic thyroid carcinomas (ATC) (61). To 
study the role of NF-κB in thyroid cancer, it was inhibited its function by stably 
transfecting FRO cells (derived from a human ATC) with a super-repressor form of 
IκBα (IκBαM). As a result, FRO IκBαM cells lost their oncogenic potential mainly 
for an increased susceptibility to drug-induced apoptosis (61). 
The cellular system FRO/FRO IκBαM represents an excellent model for the 
identification of NF-κB-regulated factors that, secreted in the extracellular milieu, 
could  play  a  role  in  thyroid  cancer.  Thus,  it  was  analyzed  by  a  differential 
proteomic approach, the pattern of expression of secreted proteins from conditioned 
medium of parental FRO cells and FRO IκBαM clones. One of the proteins that 
showed a marked decrease of expression in FRO IκBαM cells was NGAL. 
In the present PhD thesis I show that knocking down NGAL expression blocks 
the ability of FRO cells to form colonies in soft agar, to form tumor in nude mice, 
and increases  their  susceptibility  to  apoptosis.  In  addition,  I  show that  the pro-
survival  activity  of  NGAL is  mediated  by its  ability  to bind and transport  iron 
inside the cells.
22
EXPERIMENTAL PROCEDURES
Cell culture and biological reagents 
FRO, FRO IκBαM and FRO siRNA NGAL were grown in DMEM (Sigma, 
St.  Louis,  MO)  supplemented  with  10%  fetal  bovine  serum  (Sigma)  or  in 
OPTIMEM (Invitrogen, Carlsbad, CA) supplemented or not with 10% fetal bovine 
serum (Sigma). Human NGAL was amplified by PCR from a human liver c-DNA 
library (Clontech, CA) and cloned into pcDNA3.1-HA, -FLAG vectors (Invitrogen, 
Carlsbad,  CA)  for  expression  in  mammalian  cells,  and  pET28  (Novagen)  for 
expression  in  e.coli.  Human  Transferrin  was  from Kedrion  (Naples,  IT).  Anti-
NGAL (AF1757) and anti-actin (sc-8432) antibodies were purchased from R&D 
systems (Minneapolis, MN) and Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), 
respectively. A polyclonal rabbit anti-NGAL antibody was generated in rabbits by 
using human recombinant  NGAL protein as  antigen.  IL1β and IL17 were from 
Peprotech  (London,  England)  and  Biosource  (Nivelle,  Belgium),  respectively. 
Transient transfection of FRO cells was performed by using the NucleofectorTM 
(Amaxa Biosystem).
Processing of conditioned media
Conditioned  media (1 liter) from FRO and FRO IκBαM cell lines, grown in 
OPTIMEM w/o serum, were collected and centrifuged at 3500 rpm for 10 min at 
4°C to remove cells and cell debris. The samples were concentrated to 5 ml over a 
membrane pressure concentrator with a 50-kDa cut-off (Millipore, Billerica, MA) 
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and partially purified by using Mono-Q and Mono-S Econo-Pac column (Bio-Rad, 
Bedford, MA).
Two-dimensional gel electrophoresis (2-DE) analysis
The analysis was performed in triplicate on protein preparations from three 
different  batches of conditioned media.  Thyrty-fifty  μg of proteins were loaded 
onto  13  cm,  pH  3-10  L,  4-7  L  or  6-11  L  IPG  strips  (Amersham-Pharmacia 
Biosciences,  Milan,  Italy).  IEF  was  performed  using  an  IPGPhor  II  system 
(Amersham-Pharmacia Biosciences, Milan, Italy) according to the manufacturer’s 
instructions. Focused strips were equilibrated with 6.0 M urea, 26 mM DTT, 4% 
(w/v) SDS, 30% (v/v) glycerol in 0.1 M Tris-HCl (pH 6.8) for 15 min, followed by 
6.0 M urea, 0.38M iodoacetamide, 4% (w/v) SDS, 30% (v/v) glycerol, and a dash 
of bromophenol blue in 0.1 MTris-HCl (pH 6.8), for 10 min. The equilibrated strips 
were applied directly to SDS-10% (w/v) polyacrylamide gels and separated at 130 
V. Gels were fixed and stained by ammoniacal silver (6). Gels were scanned with 
an  Image  Master  2-D  apparatus  and  analysed  by  the  Melanie  5  software 
(Amersham-Pharmacia Biosciences, Milan, Italy) that allowed estimating relative 
differences in spot intensities for each represented protein. Statistical analysis of 
differentially expressed proteins was performed as previously described (4-5).
Mass spectrometry analysis
Spots from 2-DE were excised from the gel, triturated and washed with water. 
Proteins were in-gel  reduced, S-alkylated and digested with trypsin as previously 
reported  (4-5).  Digest  aliquots  were  removed  and  subjected  to  a 
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desalting/concentration step on μZipTipC18 (Millipore, Bedford, MA, USA) using 
acetonitrile as eluent before MALDI-TOFS analysis. Peptide mixtures were loaded 
on  the  MALDI  target,  using  the  dried  droplet  technique  and  α-cyano-4-
hydroxycinnamic acid as matrix, and analyzed by using Voyager-DE PRO mass 
spectrometer  (Applied  Biosystems,  Framingham,  MA,  USA).  Internal  mass 
calibration  was  performed  with  peptides  deriving  from  trypsin  autoproteolysis. 
PROWL software  package  was  used  to  identify  spots  unambiguously  (Est’d  Z 
score > 2)  from independent  non-redundant  sequence  databases  (7).  Candidates 
from peptide matching analysis were further evaluated by the comparison with their 
calculated mass and pI using the experimental values obtained from 2-DE.
siRNA of NGAL
To  knock-down  NGAL  expression,  we  designed  double-stranded 
oligonucleotides containing sequences derived from the human NGAL (nucleotides 
294-313  and  376-397)  in  forward  and  reverse  orientation  separated  by  a  7-bp 
spacer  region  (caagaga)  to  allow  the  formation  of  the  hairpin  structure  in  the 
expressed  siRNAs.  NGAL  siRNA  220:  sense  strand,  5’ 
-CCATCTATGAGCTGAAAGAcaagagaTCTTTCAGCTCATAGATGG; antisense 
strand,  5’  –CCATCTATGAGCTGAAAGAtctcttgTCTTTCAGCTCATAGATGG. 
NGAL  siRNA  2:  sense  strand,  5’  –
GGACTTTTGTTCCAGGTTGTTcaagagaAACAACCTGGAACAAAAGTCC; 
antisense  strand,  5’  –
GGACTTTTGTTCCAGGTTGTTtctcttgAACAACCTGGAACAAAAGTCC.  The 
resulting double-stranded oligonucleotides were cloned into the pcRNAi vector that 
we derived from the pcDNA3.1 vector (Invitrogen) by replacing the viral promoter-
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cassette with the H1 promoter that is specifically recognized by RNA polymerase 
III (2).
Quantification of iron content by colorimetric assay
Cell cultures in 100-mm dishes were washed twice with PBS and then lysed in 
400  μl of 50 mM NaOH for 2 h, on a shaker, in a humidified atmosphere. The 
lysates  were  incubated  for  20  min  at  room temperature  in  0.3  M HCl,  TCA-
precipitated and finally centrifuged at 1200 g for 15 min. The supernatants were 
mixed with chromogen (0.51 mM disulphonate bathophenantroline, 1.3 M sodium 
acetate, pH 4.6, 30 mM sodium pyrosulphite, 1.83 mM p-(N-methyl)aminophenol) 
and the absorbance was spectrophotometrically determined at the wavelength of 
546 nm. This method was also used to confirm the presence of iron in both human 
transferrin and recombinant NGAL.
 Immunoistochemical analysis
Specimens from normal and pathological human thyroid were isolated, rinsed 
with PBS, fixed in 4% buffered neutral formalin and embedded in paraffin. Then, 
5-6  μm thick  paraffin  sections  were  deparaffinized  and placed in  a  solution  of 
absolute methanol and 0.3% hydrogen peroxide for 30 min, then washed in PBS 
before immunoperoxidase staining. Slides were then incubated overnight at 4°C in 
a  humidified  chamber  with  antibody  anti-NGAL  diluted  1:100  in  PBS  and 
subsequently  incubated,  first  with  biotinylated  goat  anti-rabbit  IgG for  20  min 
(Vectostain ABC kits, Vector Laboratories), and then with pre-mixed reagent ABC 
(Vector) for 20 min. The antibody anti-NGAL used was a rabbit polyclonal raised 
against  the recombinant  NGAL protein. The immunostaining was performed by 
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incubating slides in diaminobenzidine (DAB-DAKO) solution containing 0.06 mM 
DAB and  2  mM  hydrogen  peroxide  in  0.05% PBS,  pH 7.6,  for  5  min.  After 
chromogen development, slides were washed, dehydrated with alcohol and xylene, 
and mounted with coverslips using a permanent mounting medium (Permount). As 
a control of the immune reaction, slides were incubated with an anti-NGAL Ab 
previously incubated with recombinant NGAL (1mg/ml).
 
Northern and Western blots
For Northern blot, 20 μg of total RNA from FRO and FRO IκBαM cell lines 
were analyzed by electrophoresis on a 1.2% formaldehyde agarose gel and blotted 
onto nitrocellulose membrane (Bio-Rad, Hercules CA). For Western blot, 20 μg of 
total proteins from cell lysates or supernatants were analyzed by 12% SDS-PAGE 
and  blotted  onto  nitrocellulose  membrane  (Schleicher  &  Schuell,  Whatman 
GmbH). Filters were blocked for 90 min at room temperature with 5% nonfat dry 
milk in TBST buffer (10mM Tris-HCl, pH 8.0, 0.1% Tween 20, 150 mM NaCl) 
and incubated with 1:2000 dilution of anti-NGAL or anti-actin antibodies 90 min. 
After TBST washing, blots were incubated for 1 h with horseradish peroxidase-
conjugated  secondary  antibodies  (Amersham  Biosciences,  NXA931)  diluted 
1:5000 in TBST buffer and then revealed by ECL (Amersham Biosciences).
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In vitro and in vivo tumorigenicity assays
To analyze the ability of the various FRO clones to form colonies in soft agar, 
1 x 104 cells were seeded in 60-mm dishes onto 0.3% Noble Agar (Difco, Detroit, 
MI) on top of a 0.6% bottom layer. Colonies larger than 50 cells were scored after 
2 weeks of incubation at 37°C. To analyze the ability of the various FRO clones to 
induce tumor growth in nude mice, 2 x 107 cells were injected s. c. on a flank of 
each 6-week-old nude mouse (Charles River, Lecco, Italy). Thirty days later, mice 
were  killed  and tumors  were  excised.  Tumor  weight  was  determined  and  their 
diameters  were measured  with caliper.  Tumors  volumes were calculated  by the 
formula:  a2  x  b  x  0.4,  where  a  is  the smallest  diameter  and  b  is  the diameter 
perpendicular to a. No mouse showed signs of wasting or other visible indications 
of toxicity. The mice were maintained at the Dipartimento di Biologia e Patologia 
Cellulare e Molecolare animal facility and housed in barrier facilities on a 12 h 
light dark cycle with food and water available ad libitum. The animal experiments 
described here were conducted in accordance with accepted standards of animal 
care and in accordance with the Italian regulations for the welfare of animals used 
in  studies  of  experimental  neoplasia,  and  the  study  was  approved  by  our 
institutional committee on animal care.
Measurement of apoptosis
2.5 x 105 cells/well were seeded in six-well culture plates and grown for 24 h 
at 37°C in the presence or in the absence of serum. In some cases cells were grown 
in  serum-free  conditioned  medium  from  FRO  cells  or  in  serum-free  medium 
containing  human  transferrin  (10  μg/ml),  recombinant  NGAL  (10  μg/ml), 
deferoxamine (200 μg/ml) or FeCl3 (50 μM). Cell death was assessed by Western 
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blot 2with anti-caspase 9 antibody (StressGen, Ann Arbor, MI) or by propidium 
iodide staining according to Nicoletti et al (3) In this case, samples were analyzed 
by flow cytometry using a CyAn cytofluoremeter (Dako) equipped with Summit 
Software. Results were mean ± S.D. of at least three separate experiments.
mRNA quantification by Real-time RT-PCR
Real-time RT-PCR was carried out with cDNAs reverse transcribed from total 
RNA using LightCycler-FastStart DNA Master SYBR Green I (Roche Diagnostic) 
using ABI PRISM 7000 software (Applied Biosystems). The primer used were 5’-
AAACAGAAGGCAGCTTTACGATG-3’  and  5’-
AAATGTTCTGATCCAGTAGCG-3’  for  NGAL,  and  5’-
TCCCAGAGCTGAACGG-3’  and  5’-GAAGTCGCGGAGACA-3’  for 
glyceraldehyde-3-phosphate dehydrogenase.
Statistics
Data were analyzed by using ANOVA test and student’s t-test analysis. Data 
are  presented as  the  means  ±SD.  P  values  less  than  0.05  were  considered 
significant.
Measurement of Mitochondrial Membrane Potential
The changes in mitochondrial membrane potential were quantified by staining 
cells with tetramethylrhodamine ethyl ester (TMRE) (Invitrogen). A TMRE stock 
was prepared at a concentration of 10 mg/ml in DMSO and stored at 20°C. Cells 
were loaded with TMRE by incubating cells in media containing 50 nM TMRE for 
30 min at 37°C.
29
Flow cytometric analysis of Cytochrome C release
Detection of cyt C release was performed as described in reference 1. 
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EXPERIMENTAL RESULTS
Differential proteomic analysis of conditioned media from FRO and FRO 
IκBαM cell lines
To  identify  factors  secreted  by  thyroid  cancer  cells  under  transcriptional 
control  of  NF-κB,  we  analyzed  the  secretome  of  partially  purified  conditioned 
media from FRO and FRO IκBαM cell lines. As shown in Fig.1A, a number of 
proteins  were  differentially  expressed  between  the  two  cell  lines.  Among  the 
proteins whose expression decreased in the extracellular medium of FRO IκBαM 
cells as compared to FRO, at least three groups of them were examined because of 
their  strong  reduction  (Fig.  1B,  circled  spots).  The  MALDI-TOF peptide  mass 
fingerprint  analysis  identified  all  spots  as  Neutrophil  Gelatinase-Associated 
Lipocalin (NGAL), whose post-translational modifications account for the multiple 
species showing variable molecular weight and pI values, in the 2-DE gel.
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IκBαM cell lines. Two-dimensional gel electrophoresis showing expression of NGAL in 
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Immunoistochemical analysis of NGAL expression in normal and pathological 
human thyroid specimens
To verify  the  expression  of  NGAL in  human  primary  thyroid  cancer,  we 
analyzed  normal  thyroid  and  specimens  from  different  thyroid  carcinomas  by 
immunostaining. As shown in Table 1 and Fig. 2 A-D, although NGAL expression 
was  not  detected  in  normal  thyroid,  NGAL  immunostaining  was  positive  for 
papillary, follicular and anaplastic thyroid carcinomas. In Fig. 2 E-F is shown the 
lack of specific  tissue  staining when secondary antibodies (Fig.  2E) or  blocked 
antibodies (Fig. 2F) were used. 
Very  interestingly,  the  levels  of  NGAL  increased  with  the  malignant 
phenotype of tumors, reaching the highest intensity in the anaplastic carcinomas 
(Table I and Fig. 2A-D), in parallel with NF-κB basal activity in the same types of 
thyroid tumors (61). Real time PCR analysis confirmed the increased expression on 
the  NGAL  mRNA  in  primary  human  thyroid  cancer  (Fig.  2G)  and  that  this 
expression parallels the NF-κB activity. 
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Hystological 
type of 
thyroid 
samples
N° of total cases 
analyzed by 
immunohistochemist
ry
N°of positive cases/ N° of 
total cases analyzed 
by 
immunoistochemistr
y
NGAL staining score
0+ 1+ 2+ 3+
Normal 
thyroid
3 0/3 3
Papillary 
carcinoma
14 9/14 5 4 3 2
Follicular 
carcinoma
8 5/8 3 2 3
Anaplastic 
carcinoma
7 6/7 1 2 4
Table I.  Immunohistochemical analysis of NGAL expression in normal and pathological 
human thyroid tissues.
Human specimens from normal thyroid, papillary,  follicular and anaplastic thyroid carcinomas 
were collected and stained with anti-NGAL polyclonal antibodies. The percentage of malignant 
cells stained was scored from 0 to 3: 0, no positive cells; 1+, <10% of positive cells; 2+, 11-60% 
of positive cells; 3+, 61-100% of positive cells.
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Fig. 2 Immunoistochemical analysis of NGAL expression in normal and pathological 
human thyroid specimens. Localization of NGAL in situ was determined by 
immunohistochemistry in sections from normal thyroid tissue (A) and three different 
anaplastic thyroid carcinomas (BD). Lack of specific tissue staining was seen when 
secondary Abs (E) or blocked Abs were used (F). Magnification, x400. G) qRT-PCR 
analysis of NGAL mRNA levels in primary human cancers. NT= normal thyroid (n=2); 
PTC=papillary thyroid carcinoma (n=3);  FTC=follicular thyroid carcinoma (n=3); 
ATC=anaplastic thyroid carcinoma (n=3). * P < 0.0005.
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NF-κB regulates NGAL expression
To confirm the differential NGAL expressione between FRO and FRO IκBαM 
cells we performed Northern and Western blot assays on total extracts from both 
FRO and FRO IκBαM cells.  As shown in Fig.  3A-C, the expression of NGAL 
mRNA and of the corresponding protein are down-regulated in FRO IκBαM cells, 
compared to parental FRO cells, according to the data from proteomic analysis. 
To confirm that NF-κB was controlling NGAL expression, we knocked down 
p65 expression in FRO cells by transfecting a siRNA (siRNA186) and a siRNA 
scrumble (siRNA1041) or the empty vector (pcRNAi) as control. We detected a 
decreased NGAL expression by Western blot (Fig. 3D) in the FRO cells transfected 
with siRNA186, while there is not reduction in the cells transfected with the control 
vectors. 
We have also  demonstrated  the NF-κB dependent  expression  of  NGAL in 
another system, by using wild type and p65-/- mouse embryonic fibroblast (MEF). 
These cells were treated with IL1β or IL17 that stimulate the NGAL expression via 
NF-κB,  and the  NGAL expression  was detected by  Northern and Western blot 
assays (Fig.  3E-F).  No induction of  NGAL was detected in absence of  p65.  In 
addition, we show that  the re-expression of p65 in p65-/- MEF restored NGAL 
expression and that this re-expression was increased by stimulation with IL1β (Fig. 
3G). 
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Fig.3 NF-κB regulates NGAL expression. The different levels of NGAL expression in 
the FRO and FRO IκBαM cell lines was analysed by Northern blot (A, top) and by Western 
blots on total cell lysates (B, top) as well as on conditioned media (C, top). The expression 
levels of NGAL mRNA were normalized to total RNA content (A, bottom), those of NGAL 
protein were normalized to actin expression in cell lysates (B, bottom) and to Coomassie 
staining of total protein in conditioned media (C, bottom). D) Expression of NGAL in FRO 
cells transiently transfected with a p65 siRNA (siRNAp65), or with the empty vector 
(pcRNAi), or with an unrelated control siRNA sequence (siRNA co) was determined by 
Western blot on total cell lysates. Induction of NGAL expression in p65-/- and wild type 
MEFs was analyzed by Northern blot (E) and Western blot (F). Induction of NGAL 
expression in p65-/- MEF reconstituted with an expression vector encoding HA-NGAL 
(G). p65-/- and wild type MEFs were treated with IL1β (20 ng/ml) or IL17 (200 ng/ml) for 
6 hours
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Inhibition of NGAL expression leads to the blockage of tumorigenicity in FRO 
cells
To study the role of NGAL in thyroid cancer we blocked its expression in 
FRO cells by stable transfection of a siRNA targeting NGAL. Figure 4A shows the 
levels of NGAL protein in two of the clones analyzed (indicated as siRNA NGAL 
2/2 and 2/6), in FRO cells transfected with the empty vector (FRO Neo cells) or 
transfected with a control siRNA (indicated as siRNA NGAL 220/22). Figure 4B 
shows the levels of secreted NGAL. These clones were tested for their ability to 
grow  in  semi  solid  medium,  and  to  form  tumor  in  nude  mice.  In  in  vitro 
experiments,  while  FRO,  FRO  Neo  and  220/22  cells  gave  rise  to  foci  of 
transformation, 2/2 and 2/6 clones did not form any colonies (Fig. 4C). In in vivo 
assays, the injection of parental FRO or 220/22 cells in nude mice induced tumor 
formation in 12 out of 12 mice, while the injection of 2/2 or 2/6 cells induced tumor 
formation in 1 out of 6 and 4 out of 6 mice, respectively (Table II). The tumors 
developed from 2/2 and 2/6 cells were, 4-fold and 2-fold smaller than that formed 
after injection of parental cells, respectively (Table II). Of note, 2 out of 4 tumors 
from  2/6  cells  showed  NGAL  staining  after  immunoistochemical  analysis, 
indicating that the expression of the siRNA plasmid was lost. We also blocked NF-
κB in FRO cells by transient overepression of IκBαM. In the absence of functional 
NF-κB,  FRO cells  did not  form colonies in  soft  agar.  Re-expression of  NGAL 
partially rescued the ability of FRO cells to form colonies in soft agar (Fig. 6A-C). 
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Fig.4 Inhibition of NGAL expression leads to the blockage of tumorigenicity in FRO 
cells. The expression of NGAL in FRO cells stably transfected with siRNA plasmids 
(2/2,2/6), control siRNA plasmid (220/22) or empty vector (Neo) was determined by 
Western blot on total cell lysates (A, top) and on conditioned media (B). C) Colony 
formation assay. Colonies larger than 50 cells were scored after 2 wk incubation at 37°C 
(D). Magnification, x200. *P<0.0001. 
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0.21 ± 0.030.33 ± 0.02 6/6FRO siRNA 
NGAL 
220/22
0.11 ± 0.02 
**
0.16 ± 0.06 
**
4/6FRO siRNA 
NGAL 2/6
0.05 ***0.01 ***1/6FRO siRNA 
NGAL 2/2
0.24 ± 0.050.37 ± 0.046/6FRO
Tumor 
weight
average
Tumor 
volume 
average 
(cm3)
Tumor 
incidence
Cell type
Table II. In vivo tumor growth induced by FRO Neo cells and FRO siRNA NGAL
clones. 2 x 107 cells were injected s. c. on a flank of each 6-week-old nude mouse. 
Tumor weight, diameter nd volume values were measured and determined as described 
in Supporting Information. Two out f four tumors developed by mice injected with 
FRO siRNA 2/6 cells showed partial NGAL taining after immunohistochemical 
analysis. ***FRO 2/2 vs. FRO: p<0.0001; **FRO 2/6 vs. FRO: < 0.001.
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NGAL is a survival factor in FRO cells
We analyzed the response of parental FRO cells and NGAL siRNA clones to 
serum withdrawal-induced apoptosis. All clones, grown in the presence of serum, 
showed 2-3% of apoptosis,  as assessed by propidium iodide staining (Fig. 5A). 
Serum deprivation did not affect the survival of FRO, FRO Neo and 220/22 clones, 
but induced a significant cell death (10-15%) in 2/2 and 2/6 clones (Fig. 5A). This 
effect was reverted by the addition of the conditioned medium of FRO cells (as 
well as of FRO Neo or 220/22 cells) to 2/2 and 2/6 clones. The same effect was 
also  seen  in  the  FRO  cells  transiently  transfected  with  IκBαM  (Fig.  6D).  To 
confirm the activation of the apoptotic machinery, we analyzed by Western blot the 
caspase-9 activity in parental FRO cells and NGAL siRNA clones grown in the 
same experimental conditions used for propidium iodide assay (Fig. 5B). Serum 
deprivation induced cleavage of caspase-9 both in 2/2 and 2/6 clones, but not in 
parental FRO cells (Fig. 5B). Also in this case, incubation of NGAL siRNA clones 
with the conditioned medium of FRO cells (as well as of FRO Neo or 220/22 cells) 
restored their survival (Fig. 5A-B). These data strongly suggest that NGAL is a 
survival factor for thyroid carcinoma cells.
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to evaluate the transfection efficiency. A) Expression of FLAG-IκBαM and HANGAL in 
the whole cell lysate (both antibodies were used). B) Transfection efficiency was 
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NGAL mediated intake of  extracellular iron accounts for the antiapoptotic 
activity of NGAL in FRO cells
One  of  the  properties  of  NGAL  is  its  ability  to  deliver  iron  from  the 
extracellular milieu into the cells. Since it has been described that iron could play 
an  important  role  in  cancer  and  apoptosis  (62),  we  tested  if  the  increased 
susceptibility  of  siRNA  NGAL  clones  to  cell  death  was  due  to  the  decreased 
NGAL-mediated delivery of iron. To this purpose, we first analyzed the ability of 
iron-loaded  transferrin  and  NGAL to  rescue  siRNA NGAL clones  from serum 
deprivation-induced  apoptosis.  As  reported  in  Figure  7,  both  propidium iodide 
staining (A) and Western blot anticaspase-9 (B) showed that addition of transferrin 
or recombinant NGAL to the serumfree medium, restored the survival of siRNA 
clones. To further confirm that NGAL acts as survival factor for cancer cells by 
delivering iron, we used DFO, an iron chelator, and ferric chloride (FeCl3), an iron 
source, to evaluate the survival of the siRNA clones. When cells were grown in 
complete medium in presence of DFO, both parental FRO cells and derived siRNA 
clones underwent apoptosis (Fig. 7C-D). On the other hand, FeCl3 produced the 
opposite  effects:  it  restored  the  resistance  of  siRNA  NGAL  clones  to  serum 
deprivation-induced apoptosis  (Fig.  7E-F).  Since these results  indicated that  the 
intracellular  iron  content  could  be  relevant  for  the  survival  of  FRO  cells,  we 
analyzed  the  intracellular  iron  concentration  of  parental  FRO cells  and  NGAL 
siRNA clones  (Fig.  8).  The  colorimetric  assay  showed that  2/2 and 2/6 clones 
lacked at least 20-30% of iron content (p<0.05) compared to FRO, FRO Neo and 
220/22 cells, thus suggesting that the absence of NGAL determined a decrease of 
iron uptake in the clones. 
44
DFR
O
2/
2
2/
6
S
DFO
+
-
+
-
+
-
+
+
+
+
+
+
-
+
-
+
-
+
47
37
35
MW
pro-caspase
cleaved
caspase9
22
0/
22
FR
O
2/
2
2/
6
22
0/
22
FR
O
2/
2
2/
6
22
0/
22
-
+
+
+
+
-
B +S
47
35
MW
pro-caspase9
cleaved
caspase9
37
-S -S +Tf -S +rNGAL
FR
O
2/
2
2/
6
22
0/
22
FR
O
2/
2
2/
6
22
0/
22
FR
O
2/
2
2/
6
22
0/
22
FR
O
2/
2
2/
6
22
0/
22
pro-caspase9
cleaved
caspase9
47
37
35
MW
S
Fe
+
-
+
-
+
-
-
-
-
-
-
-
F
FR
O
2/
2
2/
6
22
0/
22
FR
O
2/
2
2/
6
22
0/
22
FR
O
2/
2
2/
6
22
0/
22
+
-
-
- +
-
+
-
+
-
+
-
Figure 7. Iron mimicks the role of NGAL-mediated survival of FRO cells. 2.5 x 
105 cells/well were seeded in six-well culture plates and grown in different 
experimental conditions, as indicated. Cell death was assessed by propidium iodide 
staining (A, C, E) or by Western blot analysis (B, D, F). Results were mean ± S.D. 
of at least three separate experiments. S = serum; CM = conditioned medium; Tf = 
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Fig. 8 Intracellular iron content of the different FRO cell lines. Colorimetric analysis 
of intracellular iron concentration. Results were mean ± S.D. ofat least three separate 
experiments, performed in triplicate. Significantly differentfrom controls: * P < 0.05.
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Analysis of the apoptosis pathways
Apoptosis  signalings  converge  in  the  activation  of  intracellular  caspases. 
Caspases are cysteine proteases produced as inactive zymogens that cleave their 
substrates at  aspartic  acid  residues  contained  within  a  tetrapeptide  recognition 
motif.  Activation  of  initiator  caspases  (procaspase-8,  -9, -10) leads  to  the 
proteolytic  activation  of  downstream  effector  caspases (caspase-3,  -6, -7)  that 
cleave specific substrates. We can distinguish two apoptosis pathways: the death 
receptor and the mitochondrial pathway. In the death receptor pathway, the death 
receptor pathway is triggered by members of the death receptor superfamily such as 
CD95.  Binding  of  CD95-L  to  its  receptor  induces  trimerization  of  CD95  and 
formation  of  a  death-inducing complex.  This  complex  recruits,  via  the  adaptor 
molecule  FADD,  multiple  procaspase-8  molecules,  resulting  in  caspase-8 
activation.  Caspase-8  activation  can  be  blocked by  recruitment  of  c-FLIP.  The 
mitochondrial  death  pathway  is  controlled  by  members  of  the  Bcl-2  family, 
including the proapoptotic Bax and Bid proteins and the antiapoptotic Bcl-2 and 
Bcl-XL proteins. Death stimuli induce the release of cytochrome c, AIF, Apaf-1, 
Smac/DIABLO,  and  possibly  other  factors  from  mitochondria.  Cytochrome  c 
associates with Apaf-1 and caspase-9 to form the apoptosome. The death receptor 
and mitochondrial pathways converge at the level of caspase-3 activation. 
A dissection of the apoptosis pathways is illustrated in Fig. 9. In the NGAL 
siRNA clones grown in absence of serum, the initiating caspases-2 and -9 and the 
execution caspases-3/7 are activated, while the activity of other caspases, such as 
the initiating-, receptor-associated caspase-8, are not. This effect is reverted by the 
addition  of  recombinant  NGAL  (Fig.  9A).  A  very  similar  pattern  of  caspases 
activation is detected in FRO or 220/22 cells incubated with deferoxamine (DFO) 
(Fig.9B). Iron deprivation also resulted in the decrease of mitochondrial membrane 
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potential (Fig. 10A) and in the release of cytochrome C (Fig. 10B). These data 
suggest that iron deprivation induces apoptosis via collapse of the mitochondrial 
membrane potential, release of cytochrome C from mitochondria, and activation of 
execution caspases. 
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Fig.9 Analysis of the apoptosis pathway. 2.0 x 106 cells/well were grown in 
the presence (+S), of serum (+S) or in serum-free medium containing 
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at 37°C. Caspases activity was assessed by “Caspase Fluorometric Substrate Set 
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Discussion
We have identified NGAL as a mediator of the NF-κB oncogenic activity in 
thyroid cancer. NGAL is highly expressed in the human thyroid carcinoma cell line 
FRO, and also other poorly differentiated thyroid cancer cell lines, (Fig. 1A and 
data  not  shown),  is  highly  expressed  in  primary  human  anaplastic  thyroid 
carcinomas (Fig. 1B-D and Table I) and acts as a survival factor for thyroid cancer 
cells (Fig. 5, 6, 7). The pro-survival activity of NGAL is mediated by its ability to 
bind iron and to transport  it  inside the cells  (Fig.  7-8).  These findings identify 
NGAL as a critical effector of the NF-κB-mediated oncogenic activity, define a 
pro-survival function for NGAL, and highlight iron as a central controller of cell 
survival. Various types of cancers express high levels of NGAL, including colon, 
pancreas, breast, bladder and liver (48-52). NGAL represents the human homolog 
of  the  rat  neu-related  lipocalin  (NRL),  a  gene  which  was  shown  to  be 
overexpressed in HER-2/neu oncogene induced rat mammary tumors (63). Whether 
NGAL is causal or contributory to cancer is unknown. It has been reported that 
NGAL is a surviving factor for cancer cells. Ectopic expression of NGAL in lung 
and breast cancer cell lines reduced apoptosis induced by a PDK1 inhibitor, and 
decreased expression of NGAL by siRNA had opposite effects (57). Our results 
confirm that NGAL is a surviving factor for cancer cells, and extend these findings 
by demonstrating that the protective effect of NGAL is mediated by its ability to 
bind and transport iron. Our results are in agreement with the model proposed by 
Devireddy et al. (56). In this model, it is proposed that internalization of the apo 
form of NGAL leads to iron loss and apoptosis. Conversely, internalization of iron-
loaded NGAL might prevent apoptosis. Iron contributes to enzyme activity in DNA 
synthesis, metabolism and oxygen response, and its acquisition plays a critical role 
in  development,  cell  growth  and  survival  (62).  Cancer  cells  have  a  higher 
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requirement for iron than normal cells, as they rapidly proliferate. This is reflected 
by the evidence that tumor cells have higher numbers of transferrin receptors on 
their surface, mediating a high rate of iron uptake (64). The importance of keeping 
constant the levels of iron uptake is further suggested by the evidence that multiple 
and redundant systems for iron uptake and transport exist. Most cells acquire iron 
by capturing iron loaded transferrin. However, 10 hypotransferrinemic mice (65-
66)  and  humans  (67)  have  defects  in  central  nervous  system development  and 
hematopoiesis, but most epithelial organs are normal. Likewise, the mice lacking 
the  transferrin  receptor  1  initiate  organogenesis  but  succumb  to  the  effects  of 
anemia  (68).  Given that  iron is  necessary for  all  the  cells,  there must  be other 
pathways for iron acquisition in epithelial cells. One of such pathway is mediated 
by NGAL. In our experimental model, we observed that cells knocked-down for 
NGAL  expression  showed  a  decrease  of  about  20-30%  in  iron  content;  this 
decrease  still  allowed cell  surviving.  However,  if  the  iron  delivery  was  further 
decreased,  or  cells  were  exposed  to  an  appropriate  stress,  such  as  serum 
deprivation, cells underwent apoptosis. Indeed, administration of iron, either as iron 
salt, transferrin or iron-loaded NGAL, restored the ability of knocked-down cells to 
survive in the absence of serum. Similarly, knock out mice for NGAL are vital and 
do  not  show  gross  developmental  defects,  although  they  succumb  to  bacterial 
infection  (69).  Many  studies  have  demonstrated  that  iron  chelators,  such  as 
deferoxamine (DFO), have effective anticancer activity (70). Iron is essential for 
the  catalytic  activity  of  ribonucleotide  reductase,  an  enzyme  mediating  the 
conversion of all four ribonucleotides to their deoxyribonucleotide counterparts, the 
rate-limiting step of DNA synthesis (71). However, in our experimental system, the 
proliferation rate of the cells knocked-down for NGAL expression is not affected 
(data  not  shown).  Iron  levels  strictly  control  the  activity  of  specific  prolyl 
hydroxylase-domain  enzymes  (PHDs),  which,  in  turn,  promote  functional 
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activation of transcription factors involved in tumor development, as is the case of 
the HIF-1,  which controls genes involved in energy metabolism and angiogenesis 
(72). HIF-1 is primarily regulated by specific PHDs that initiate its degradation via 
the von Hippel-Lindau tumour  suppressor  protein (VHL).  The oxygen and iron 
dependency of PHD activity accounts for regulation of the pathway by both cellular 
oxygen and iron status.  We have evidence  that  in  our  experimental  system the 
protein level of HIF-1α is increased in the NGAL knockdown clones, and is down-
regulated by the addition of iron. Conversely, in control cells, the level of HIF-1α 
protein is low and is up-regulated by the addition of DFO. Moreover, the activity of 
a HIF1-responsive promoter parallels the level of HIF-1 protein (Data not shown). 
Since NF- κB is a central component in the hypoxic response in that it positively 
regulates HIF1 1α expression (73), it is tempting to speculate that the involvement 
of  NGAL  as  an  iron  transporter,  as  well  as  its  opposing  effect  on  HIF-1α 
expression,  could  be  a  part  of  an  auto-regulatory  loop with  inhibitory  function 
between NF-κB and HIF-1 that could control tumor progression. Modulation of cell 
survival may not be the only way NGAL influence the behaviour of a cancer cell. 
NGAL has been demonstrated to form a complex with MMP-9, playing a role in 
the  maintenance  of  an  extracellular  pool  of  a  potentially  active  form  of  the 
protease,  whose activity is associated with angiogenesis and tumor growth (55). 
This is supported by the evidence that the level of NGAL expression correlates 
with the clinical  outcome of  the patients  and also with the depth of  the tumor 
invasion (56). We have evidence that a complex between NGAL and MMP9 also 
exists in transformed thyroid cells, although nor the exact role that such as complex 
plays in thyroid cancer is known, neither if the activity of MMP9 is affected by the 
presence  of  NGAL.  In  other  experimental  systems  NGAL  has  been  shown  to 
induce expression of E-cadherin, to promote formation of polarized epithelia and to 
diminish  invasiveness  of  Ras-transformed  cell  lines  (74).  In  our  experimental 
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system, NGAL seems to have a different role. In fact, ectopic expression of NGAL 
in normal thyroid cell line, or its knock-down in transformed cells, does not alter 
the expression of E-cadherin nor vimentin (data not shown). Our results, in addition 
to identify NGAL as a potential target for therapeutic intervention, also strengthens 
the rationale for the use of iron chelators in the treatment of cancer. Depleting iron 
from a rapidly dividing cancer cell, through the implementation of iron chelators, 
or decreasing NGAL expression,  deprives it  of a component critical for various 
cellular processes and induces apoptosis.  
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